Get the Stockscreener App
7.70
2.29%
-0.15
Zenas Biopharma Inc stock is traded at $7.70, with a volume of 179.17K.
It is down -2.29% in the last 24 hours and down -21.49% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$7.85
Open:
$7.82
24h Volume:
179.17K
Relative Volume:
0.59
Market Cap:
$321.37M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.36%
1M Performance:
-21.49%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.4364
$7.96
1-Week Range:
$7.25
$8.1108
52-Week Range:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
1000 WINTER ST, SUITE 1200, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
7.695 | 321.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.10 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.65 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.58 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.02 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.34 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Zenas BioPharma Targets Key 2025 Milestones For Obexelimab In Autoimmune Diseases - BERNAMA
ZENAS BIOPHARMA TARGETS KEY 2025 MILESTONES FOR OBEXELIMAB IN AUTOIMMUNE DISEASES - BERNAMA
ZENAS BIOPHARMA ANNOUNCES KEY 2024 ACCOMPLISHMENTS AND 2025 BUSINESS OBJECTIVES TO SUPPORT THE GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF THERAPIES FOR AUTOIMMUNE DISEASES - BERNAMA
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives - Marketscreener.com
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 - GlobeNewswire
Wolfe Research Initiates Coverage of Zenas BioPharma (ZBIO) with Outperform Recommendation - MSN
Zenas BioPharma initiated with an Outperform at Wolfe Research - MSN
Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target - Marketscreener.com
Zenas Biopharma To Present At Guggenheim SMID Cap Biotech Conference On Feb 5 - BERNAMA
ZENAS BIOPHARMA TO PRESENT AT THE GUGGENHEIM SMID CAP BIOTECH CONFERENCE - BERNAMA
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Zenas BioPharma Takes Center Stage: Key Revelations Expected at Major Biotech Summit - StockTitan
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
Zenas BioPharma initiated with a Buy at H.C. Wainwright - Yahoo Finance
HC Wainwright & Co. Initiates Coverage of Zenas BioPharma (ZBIO) with Buy Recommendation - MSN
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
H.C. Wainwright starts Zenas stock with Buy rating, eyes Obexelimab’s role in autoimmune treatment - Investing.com Australia
Guggenheim maintains buy on ZBIO shares, sees strong drug potential By Investing.com - Investing.com Canada
Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley - Yahoo Finance
Zenas BioPharma CEO Leon O. Moulder Jr. purchases $718,100 in stock - Investing.com
Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 By Investing.com - Investing.com South Africa
Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 - Investing.com
Zenas BioPharma Inc. (ZBIO) Quarterly 10-Q Report - Quartz
FMR LLC Acquires New Stake in Zenas BioPharma Inc - GuruFocus.com
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Zenas BioPharma Raises $259M in IPO, Advances Phase 3 Trial Amid Growing R&D Investment | ZBIO Stock News - StockTitan
Zenas BioPharma Completes Targeted Enrollment of the Phase - GlobeNewswire
Zenas BioPharma Hits Milestone: Completes Enrollment in Largest-Ever IgG4-RD Trial | ZBIO Stock News - StockTitan
Zenas BioPharma To Attend Upcoming Healthcare Investor Conferences - BERNAMA
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences - BERNAMA
TSX Global Base Metals EW Index (TXBE) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Arm Holdings Plc ADR (ARM-Q) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Zenas Bio: Recent IPO With Late-Stage Candidate (NASDAQ:ZBIO) - Seeking Alpha
Biopharma financing drops in Q3, but is outpacing last two years - BioWorld Online
Zenas started at buy by four banks on lead drug potential (NASDAQ:ZBIO) - Seeking Alpha
Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab - Investing.com Canada
Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum - Investing.com Canada
Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials - Investing.com Canada
Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials - Investing.com Canada
Biopharma financings surge to $86.2B in 2024, with $8.7B in September - BioWorld Online
Halda appoints new chief executive - The Pharma Letter
IgG4-related Disease Market to Show Remarkable Growth Trends - openPR
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
Zenas BioPharma CEO acquires $360k worth of company shares - Investing.com India
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
| ENRIGHT PATRICK G | Director |
Sep 16 '24 |
Buy |
17.00 |
440,000 |
7,480,000 |
774,530 |
| Nunn Jason Raleigh | Director |
Sep 16 '24 |
Buy |
17.00 |
882,352 |
14,999,984 |
1,946,564 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):